We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC ® small molecules toward key clinical milestones,” said Pratik Shah, Ph.D., ...

City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced additions to its executive team and board of directors ...

AbCellera faces challenges as it shifts to internal development, impacting revenue. It retains a large cash position. Read ...